Contents: Glipizide

Treatment of type 2 DM.

Initial dose: 2.5-5 mg daily. Max: 20 mg daily or up to 15 mg may be given as single doses (higher doses are given in divided doses).

: Hypersensitivity. Type 1 DM, diabetic ketoacidosis w/ or w/o coma.

Special Precautions: Renal & hepatic impairment. Increased CV mortality. Hypoglycemia may occur especially in elderly, debilitated or malnourished patients. Monitor blood & urine glucose periodically. Pregnancy & lactation.

Adverse Drug Reactions
: Nausea, vomiting, epigastric fullness, heartburn. Allergic skin reactions, eczema, pruritis, erythema, urticaria.

Drug Interactions
: Hypoglycemic action potentiated by NSAIDs, azoles & other drugs that are highly protein bound eg salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs & β-adrenergic blocking agents. Hyperglycemic effects w/ thiazides & other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, OCs, phenytoin, nicotinic acid, sympathomimetics, Ca channel blockers & INH.

Pregnancy Category (US FDA):
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

MIMS Class:
Antidiabetic Agents

ATC Classification
: A10BB07 - glipizide ; Belongs to the class of sulfonamides, urea derivatives. Used in the treatment of diabetes.

Regulatory Classification: Rx
Reference: mims

Watch out for our new products. Coming out soon.

All Rights Reserved. Khriz Pharma. ©2014-2015